Feature | November 04, 2013

Event-Free Patients May Not Need Long-Term DAPT After PCI

Results of the ARCTIC-INTERRUPTION Trial Presented at TCT 2013

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic
November 4, 2013 — Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT) according to the results from the ARCTIC-INTERRUPTION trial, which was presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
The optimal length of time for DAPT after coronary stenting remains uncertain with an unknown safety-to-efficacy ratio of prolonged therapy. Currently, there are discrepancies between international guidelines and high variability in routine practice. The ARCTIC-INTERRUPTION study was a prospective, randomized trial that examined the benefit of the continuation of DAPT for up to two years. 
 
ARCTIC-INTERRUPTION randomly assigned 1,259 patients without major events within the first year after coronary stenting to either a strategy of interruption of DAPT (n = 624) or a strategy of continuation for an additional year (n = 635). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke or urgent revascularization after one year. 
 
The primary endpoint occurred in 3.8 percent of patients in the continuation group as compared to 4.3 percent in the interruption group. The main secondary endpoint of stent thrombosis or any urgent revascularization occurred in 1.3 percent of patients in the continuation group and 1.6 percent of those in the interruption group. The rate of major bleeding events occurred in 1.1 percent of the patients in the continuation group compared to 0.2 percent in the interruption group. 
 
“The ARCTIC-INTERRUPTION study suggests no ischemic benefit of DAPT continuation beyond one year after stenting in patients that do not experience an adverse event within the first year,” said Gilles Montalescot, M.D., Ph.D., professor of cardiology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France, and lead investigator of the study. “Further, the study found significantly more major and minor bleeding events with DAPT continuation." 
 
For more information: www.crf.org

Related Content

PFO occluder, amplatzer
Feature | Structural Heart Occluders| May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
radial access, transradial
Feature | Radial Access| May 27, 2016 | Dave Fornell
The use of transradial artery vascular access for percutaneous coronary intervention (PCI) in the United States has s
Ambio Health telemonitoring system, LifeBridge Health Cardiovascular Institute, Baltimore, pilot study
News | Remote Monitoring| May 26, 2016
The LifeBridge Health Cardiovascular Institute, Baltimore, has launched a pilot study to evaluate the potential...
Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
cath lab, radiation exposure, glocoma
Feature | Radiation Dose Management| May 26, 2016 | Dave Fornell
May 27, 2016 — Radiation exposure to cath lab staff and physicians has seen growing concern in recent years, as the p
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Overlay Init